Edward Taylor joined the IR2Dx Canada Board of Directors in June 2013. He has over 30 years of general management experience in finance, management accounting, information systems and human resources. During his 13 years as Chief Financial Officer for Oncothyreon/Biomira, he raised over $300 million in public offerings in Canada and the U.S. using a variety of financial vehicles. From 1989 to 1995, Mr. Taylor served as a key member of a four-man management team, and as Vice President, Administration of Alberta-Pacific Forest Industries, an international joint venture formed to build and operate a $1.3 billion pulp mill facility in north Central Alberta. The operating mill employed over 1,100 people. Earlier, he worked with Crestbrook Forest Industries for over 12 years in various financial positions. Mr. Taylor served as a Board Member of the British Columbia Institute of Technology for ten years, including one year as Chairman, and was an elected Public School Trustee for six years. He also was on the Board of Governor’s Audit Committee of the University of Alberta. He currently serves as the Chair of the Board of Directors of Ceapro Inc., a publicly traded biotech company.
Mr. Taylor earned a CGA degree from the University of British Columbia, and graduated from the Stanford Executive Business Program at Stanford University. He’s a Certified General Accountant, and a member of the Certified General Accountants Association of Alberta, Canada.
Michael Obert joined the IR2Dx Canada Board of Directors in 2010. He recently retired as a partner at Dentons, an international legal practice. Prior thereto he served as Chief Legal Officer, SVP Corporate Development and a member of the Executive Leadership Team of a publicly traded life sciences company. Mr. Obert has extensive senior legal and business experience, both domestically and internationally, in the corporate-commercial, technology/IP and life sciences areas. He has worked on major collaboration, joint venture, M&A, technology licensing, public and private financing, and other similar transactions. He currently serves on a number of boards of technology/life science and non-profit organizations.
Mr. Obert earned a B.S., with honors, from McGill University, an M.A. from Queen’s University, and an LL.B from the University of Toronto.
Dr. Alex McPherson joined the IR2Dx Board of Directors in April 2012. He served as President and CEO of Biomira, Inc. from October of 1991 until his retirement in May 2006. He joined the Board of Directors of Biomira in 1987, and was later appointed as CEO. He has served as a professor for 25 years at the University of Alberta (Canada) and is currently Professor Emeritus. Dr. McPherson was the Director of Medicine at the Cross Cancer Institute in Edmonton from 1972-1985, and the Deputy Minister of Health in Alberta, the highest appointed position in the Provincial Department of Health with 2,500 employees and a budget of over $5 billion. He also served as Deputy Commissioner and Executive Director of the Premier’s Commission on Future Health Care for Albertans from 1985 – 1990. In previous years he was elected as President of the Alberta Medical Association and the Canadian Medical Association. Dr. McPherson has served as Director of Biotechnology Industry Organization (BIO), Biotec Canada and the Alberta Biotech Association. He currently sits on the board of several public and private companies. He is an immuno-oncologist and has the following degrees and professional qualifications: FRACP (Australasian College of Physicians; FACP (American College of Physicians); and FRCP(C) Canadian College of Physicians.
Dr. McPherson earned his medical degree from the University of Alberta, Canada in 1962, and his PhD from the University of Melborne in Australia in 1969.
Phil Donenberg joined the IR2Dx Board of Directors in April 2012. Mr. Donenberg is Senior Vice President, Chief Financial Officer of AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for rare and life-threatening neurological diseases. He previously served as Chief Financial Officer of RestorGenex, and BioSante Pharmaceuticals, Inc.’s (NASDAQ:BPAX) Senior Vice President of Finance from 2010 until June 2013, and Chief Financial Officer and Secretary from 1998 until June 2013, when BioSante merged with ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc. BioSante was a specialty pharmaceutical company focused on developing products for women’s and men’s health and oncology. From 1995 to 1998, Mr. Donenberg was Controller of Unimed Pharmaceuticals, Inc. (currently a wholly owned subsidiary of AbbVie Inc.), a company with a product focus on infectious diseases, AIDS, endocrinology and oncology. Prior to Unimed Pharmaceuticals, Inc., he held similar positions with several other pharmaceutical companies, including Gynex Pharmaceuticals, Inc. (currently Savient Pharmaceuticals, Inc.), Applied NeuroSolutions, Inc. and Xtramedics, Inc. For the past seven years, he has been a frequent guest lecturer for various MBA and Undergraduate College of Business classes at the University of Illinois Champaign-Urbana and Lake Forest Graduate School of Management.
Mr. Donenberg earned a B.S. in Accountancy from the University of Illinois Champaign-Urbana College of Business, and is a Certified Public Accountant.
Dr. Paul R. Billings M.D., Ph.D. joined the Board of Directors in August, 2015 and serves as a Consultant in Strategy, Alliances and Competitive Intelligence for IR2Dx. Dr. Billings has extensive expertise and health care experience in the areas of genomics, molecular medicine, personalized medicine and diagnostics. He’s a Board certified internist and clinical geneticist. He currently is CMO and Senior Vice President of Medical Affairs of Natera, a company focused on noninvasive prenatal genetic testing and screening. He has served on the Scientific Advisory Board of the Food and Drug Administration and the Genomic Medicine Advisory Committee at the Department of Veterans Affairs. Dr. Billings was the Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital, the largest community hospital in the Silicon Valley. He was the former Chief Medical Officer of Life Technologies Inc. and the Genetic Sciences Division of ThermoFisher Scientific, both unique positions aimed at improving patient care using medically relevant genomic technologies in clinical settings. He has been a founder or chief executive officer of several companies involved in genetic and personalized diagnostic medicine, a director of others, and was senior vice president for corporate development at Laboratory Corporation of America Holdings (NYSE; LH).
Dr. Billings has had a distinguished career as a physician and researcher. He has held academic appointments at Harvard University, U.C. San Francisco, Stanford University and U.C. Berkeley, and has served as a physician at a number of leading medical centers. He is the author of nearly 200 publications and books on experimental and clinical medicine. Dr. Billings holds an M.D. from Harvard Medical School and a Ph.D. in immunology from Harvard University.